Back

Biography

Manju Ray is an Indian scientist in Molecular Enzymology and Cancer Biochemistry. She has done notable work in the development of anticancer drug and understanding of differentiation process of cells. Her interests cover tumor biochemistry and molecular enzymology.

Abstract

The anticancer eff ect of methylglyoxal has been known for a long time. But relatively recent work has shown that it acts exclusively against malignant cellular mitochondrial complex I and GAPDH to elicit its anticancer eff ect. With the primary objective to treat cancer patients by methylglyoxal its toxicity was assessed at fi rst by administering through three diff erent routes to four diff erent species of animals. Having found that methylglyoxal is potentially safe for human consumption and able to destroy cancer cells in vivo a methylglyoxal-based anticancer formulation was administered orally to diverse groups of cancer patients with the due permission from regulatory authorities. Th e patients were divided in three study groups. In fi rst group (14 months, January 2000-February 2001) 24 patients were recruited and complete remission was observed for 11 patients and partial remission for 5 patients. In the second group (60 months, October 2000-September 2005) 46 patients were recruited and complete remission was observed for 18 patients and partial remission for 18 patients. In the third group (42 months, May 2005-October 2008) of the 23 patients complete remission was observed for 11 patients and partial remission for 7 patients. Th e treatment was found to be especially eff ective for adenocarcinoma of urinary bladder, breast, uterus, esophageal and gastrointestinal tract cancer. Several vital biochemical, radiological and other parameters were tested in patients who received treatment for a long time to assess the possible long term toxicity of methylglyoxal treatment, if any, and the results implicated no toxicity as per the parameter studied. All the results showed great promise of methylglyoxal treatment and demands further improvisation the methylglyoxal based therapeutics.